AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31863134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative radiographs (IR) assessment by orthopedic trauma surgeons
Number of subjects: 30
Study 31863134 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiograph requests
Number of subjects: 30
Study 31863134 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative CT requests
Number of subjects: 30
Study 31863134 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer reliability
Number of subjects: 30
Study 29129715 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted Diabetes Prevention Program Group Lifestyle Balance (DPP GLB) intervention, details on dosage and duration not specified.
Number of subjects: 0
Study 29129715 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive adaptations during intervention delivery, details on dosage and duration not specified.
Number of subjects: 0
Study 27145396 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Lee Silverman Voice Treatment (LSVT LOUD)
Number of subjects: 31
Study 27145396 — intervention group
Group type: COMPARATOR
Intervention: Face‐to‐face Lee Silverman Voice Treatment (LSVT LOUD)
Number of subjects: 31
Study 27145396 — intervention group
Group type: EXPERIMENTAL
Intervention: Online treatment (nonmetropolitan cohort)
Number of subjects: 31
Study 27145396 — intervention group
Group type: EXPERIMENTAL
Intervention: Online treatment (metropolitan cohort)
Number of subjects: 31
Study 24509430 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol + Reboxetine
Number of subjects: 19
Study 24509430 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine + Reboxetine
Number of subjects: 19
Study 24509430 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Reboxetine
Number of subjects: 19
Study 23565787 — intervention group
Group type: EXPERIMENTAL
Intervention: Spaced training
Number of subjects: 0
Study 23565787 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategically massed training
Number of subjects: 0
Study 23565787 — intervention group
Group type: COMPARATOR
Intervention: Randomly massed training
Number of subjects: 0
Study 21161380 — intervention group
Group type: COMPARATOR
Intervention: Fasting for 12 hours before CE (Group A, n = 23)
Number of subjects: 68
Study 21161380 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 liters of polyethylene glycol (PEG) (Group B, n = 20)
Number of subjects: 68
Study 21161380 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 liters of polyethylene glycol (PEG) (Group C, n = 25)
Number of subjects: 68
Study 18374304 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face cognitive-behavioral therapy (FTF-CBT)
Number of subjects: 128
Study 18374304 — intervention group
Group type: COMPARATOR
Intervention: Telemedicine cognitive-behavioral therapy (TV-CBT)
Number of subjects: 128
Study 17134621 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (40 IU)
Number of subjects: 325
Study 17134621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 14500059 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized modified Burch colposuspension added to planned abdominal sacrocolpopexy
Number of subjects: 91
Study 14500059 — intervention group
Group type: COMPARATOR
Intervention: Planned abdominal sacrocolpopexy without Burch colposuspension
Number of subjects: 91
Study 14500059 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative urodynamic testing with prolapse reduction
Number of subjects: 91
Study 14500059 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized questionnaires and physical observations
Number of subjects: 91
Study 11198206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin IgG, 0.4 g/kg body weight/day for 5 consecutive days, followed by single booster doses of 0.4 g/kg/day, once a month for 9 months
Number of subjects: 13
Study 11198206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 11198206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin IgG
Number of subjects: 13
Study 8833099 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g/kg/day alcohol
Number of subjects: 0
Study 8833099 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g/kg/day alcohol
Number of subjects: 0
Study 8833099 — intervention group
Group type: COMPARATOR
Intervention: 0 g/kg/day alcohol (control)
Number of subjects: 0
Study 1428567 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% maleate timolol, twice a day for 7 days
Number of subjects: 12
Study 1428567 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated contralateral eyes)
Number of subjects: 12
Study 6776576 — intervention group
Group type: EXPERIMENTAL
Intervention: (‐)‐deprenyl (5‐10 mg/day for 3 days)
Number of subjects: 6
Study 6776576 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 6
Study 30308286 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily breath alcohol monitoring with reinforcement for alcohol-negative breath samples
Number of subjects: 19
Study 30308286 — intervention group
Group type: COMPARATOR
Intervention: Daily breath alcohol monitoring without reinforcement
Number of subjects: 19
Study 30308286 — intervention group
Group type: COMPARATOR
Intervention: Transdermal alcohol monitoring
Number of subjects: 19
Study 30308286 — intervention group
Group type: COMPARATOR
Intervention: Self-report data
Number of subjects: 19
Study 30308286 — intervention group
Group type: COMPARATOR
Intervention: BrAC monitoring
Number of subjects: 19
Study 30308286 — intervention group
Group type: COMPARATOR
Intervention: Transdermal monitoring
Number of subjects: 19
Study 30308286 — intervention group
Group type: COMPARATOR
Intervention: Self-report monitoring
Number of subjects: 19
Study 28114607 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping (≥180 seconds after delivery)
Number of subjects: 540
Study 25796293 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone with analgesia information sheet
Number of subjects: 0
Study 25796293 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative information without analgesia information sheet
Number of subjects: 0
Study 23389323 — intervention group
Group type: EXPERIMENTAL
Intervention: sertraline hydrochloride (50 mg/d) + active tDCS (2‐mA anodal left/cathodal right prefrontal tDCS, twelve 30‐minute sessions)
Number of subjects: 120
Study 23389323 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS only (2‐mA anodal left/cathodal right prefrontal tDCS, twelve 30‐minute sessions)
Number of subjects: 120
Study 23389323 — intervention group
Group type: COMPARATOR
Intervention: placebo/sham tDCS
Number of subjects: 120
Study 23389323 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS only
Number of subjects: 120
Study 23389323 — intervention group
Group type: EXPERIMENTAL
Intervention: active tDCS
Number of subjects: 120
Study 20623280 — intervention group
Group type: EXPERIMENTAL
Intervention: Full weightbearing after cementless total hip arthroplasty
Number of subjects: 100
Study 20623280 — intervention group
Group type: COMPARATOR
Intervention: Partial weightbearing after cementless total hip arthroplasty
Number of subjects: 100
Study 19779953 — intervention group
Group type: EXPERIMENTAL
Intervention: vitalHEAT system
Number of subjects: 55
Study 19779953 — intervention group
Group type: COMPARATOR
Intervention: Bair Hugger
Number of subjects: 55
Study 17069818 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (IRB; 300 mg/d) for 12 weeks
Number of subjects: 18
Study 17069818 — intervention group
Group type: COMPARATOR
Intervention: Losartan (10(‐5) mol/L)
Number of subjects: 18
Study 17069818 — intervention group
Group type: COMPARATOR
Intervention: LY311727 (10(‐5) mol/L)
Number of subjects: 18
Study 16898905 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ALA
Number of subjects: 12
Study 16898905 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% ALA
Number of subjects: 12
Study 16898905 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% ALA
Number of subjects: 12
Study 14500434 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylxanthines
Number of subjects: 169
Study 14500434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study 10194425 — intervention group
Group type: EXPERIMENTAL
Intervention: FAI + ATRA
Number of subjects: 215
Study 10194425 — intervention group
Group type: EXPERIMENTAL
Intervention: FAI + G-CSF
Number of subjects: 215
Study 10194425 — intervention group
Group type: EXPERIMENTAL
Intervention: FAI + ATRA + G-CSF
Number of subjects: 215
Study 10194425 — intervention group
Group type: COMPARATOR
Intervention: FAI
Number of subjects: 215
Study 10194425 — intervention group
Group type: EXPERIMENTAL
Intervention: FAI + G-CSF + ATRA
Number of subjects: 215
Study 8576656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynorphin 180 micrograms/kg
Number of subjects: 21
Study 8576656 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynorphin 60 micrograms/kg
Number of subjects: 21
Study 8576656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 micrograms/kg)
Number of subjects: 21
Study 2089047 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 8
Study 2089047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6106781 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mercaptoethane sulphonate sodium (mesnum)
Number of subjects: 8
Study 6106781 — intervention group
Group type: COMPARATOR
Intervention: Isophosphamide alone
Number of subjects: 8
Study 6106781 — intervention group
Group type: EXPERIMENTAL
Intervention: Isophosphamide with mesnum (4 to 8 g/m2)
Number of subjects: 8
Study 31240727 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet intervention (deprexis)
Number of subjects: 223
Study 29705674 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured personal care
Number of subjects: 1381
Study 29705674 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 1381
Study 28251722 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning learning session with positive, neutral or negative valenced cues
Number of subjects: 386
Study 28251722 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening learning session with positive, neutral or negative valenced cues
Number of subjects: 386
Study 28251722 — intervention group
Group type: EXPERIMENTAL
Intervention: Relearning with the same word-pairs one week later
Number of subjects: 386
Study 28251722 — intervention group
Group type: COMPARATOR
Intervention: Sleep (compared to no sleep)
Number of subjects: 386
Study 25782657 — intervention group
Group type: COMPARATOR
Intervention: Probiotic milk containing Lactobacillus rhamnosus GG, L acidophilus La-5, and Bifidobacterium animalis subsp. lactis Bb-12, administered from 36 weeks of gestation to 3 months postnatally.
Number of subjects: 0
Study 25782657 — intervention group
Group type: COMPARATOR
Intervention: Probiotic milk (Lactobacillus rhamnosus GG)
Number of subjects: 0
Study 25782657 — intervention group
Group type: COMPARATOR
Intervention: Probiotic milk and placebo
Number of subjects: 0
Study 23787030 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-weeks of combination nicotine replacement therapy (NRT) in conjunction with brief counseling (SBIRT framework) (n=23)
Number of subjects: 40
Study 23787030 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=17)
Number of subjects: 40
Study 20947208 — intervention group
Group type: EXPERIMENTAL
Intervention: Prewired electrodes
Number of subjects: 105
Study 20947208 — intervention group
Group type: COMPARATOR
Intervention: Conventional electrodes
Number of subjects: 105
Study 18787321 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based resistance and balance training (RBT)
Number of subjects: 167
Study 18787321 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance and balance training (RBT)
Number of subjects: 167
Study 18787321 — intervention group
Group type: COMPARATOR
Intervention: Group-based walking
Number of subjects: 167
Study 16855076 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (4 mg/kg; maximal dose 300 mg)
Number of subjects: 60
Study 16855076 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/acetaminophen (10/650 mg)
Number of subjects: 60
Study 16855076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16855076 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (diphenhydramine, 50 mg)
Number of subjects: 60
Study 12806229 — intervention group
Group type: EXPERIMENTAL
Intervention: Total circulatory arrest or low‐flow cardiopulmonary bypass (not specified which is I or C)
Number of subjects: 155
Study 12806229 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 155
Study 10818327 — intervention group
Group type: EXPERIMENTAL
Intervention: remifentanil + isoflurane (0.6 vol% end-tidal)
Number of subjects: 249
Study 10818327 — intervention group
Group type: COMPARATOR
Intervention: remifentanil + propofol (0.1 mg/kg/min)
Number of subjects: 249
Study 9045235 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbo Spin Echo (TSE) sequences
Number of subjects: 36
Study 9045235 — intervention group
Group type: COMPARATOR
Intervention: Conventional Spin Echo (SE) sequences
Number of subjects: 36
Study 1891509 — intervention group
Group type: EXPERIMENTAL
Intervention: MCPP (meta‐chlorophenylpiperazine)
Number of subjects: 72
Study 6623770 — intervention group
Group type: EXPERIMENTAL
Intervention: 5,000 units of subcutaneous heparin three hours preoperatively and every twelve hours thereafter for forty-eight hours
Number of subjects: 34
Study 6623770 — intervention group
Group type: COMPARATOR
Intervention: Normal saline injections in a similar manner
Number of subjects: 34
Study 31918039 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined action observation and motor imagery (AO + MI)
Number of subjects: 20
Study 31918039 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated videos with no motor content)
Number of subjects: 20
Study 31014938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation (TR) program, breathing and calisthenic exercises, three times a week for 6 weeks, via internet-based video conferences.
Number of subjects: 50
Study 31014938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 50
Study 29759717 — intervention group
Group type: EXPERIMENTAL
Intervention: Active LLVNS
Number of subjects: 54
Study 29759717 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 54
Study 27658192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive reappraisal (CR)
Number of subjects: 72
Study 24924292 — intervention group
Group type: EXPERIMENTAL
Intervention: NOCTP
Number of subjects: 230
Study 24924292 — intervention group
Group type: EXPERIMENTAL
Intervention: IPFA
Number of subjects: 230
Study 24924292 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 230
Study 22041543 — intervention group
Group type: EXPERIMENTAL
Intervention: Garlic fermented with Monascus pilosus (MGFE)
Number of subjects: 55
Study 22041543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 19619020 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 0
Study 19619020 — intervention group
Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 0
Study 17461902 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (T) 75 mg/m(2), epirubicin (E) 75 mg/m(2), cyclophosphamide (C) 500 mg/m(2) IV
Number of subjects: 15
Study 17461902 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel (T) 100 mg/m(2), epirubicin (E) 100 mg/m(2), cyclophosphamide (C) 500 mg/m(2) IV
Number of subjects: 15
Study 15033849 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic use in RSV infected children
Number of subjects: 1795
Study 15033849 — intervention group
Group type: COMPARATOR
Intervention: RSV infection with risk factors
Number of subjects: 1795
Study 11243558 — intervention group
Group type: EXPERIMENTAL
Intervention: B&L pinch gauge
Number of subjects: 40
Study 11243558 — intervention group
Group type: EXPERIMENTAL
Intervention: JTech pinch gauge
Number of subjects: 40
Study 11243558 — intervention group
Group type: EXPERIMENTAL
Intervention: NK pinch gauge
Number of subjects: 40
Study 11243558 — intervention group
Group type: EXPERIMENTAL
Intervention: All pinch gauges
Number of subjects: 40
Study 9143213 — intervention group
Group type: EXPERIMENTAL
Intervention: Spa therapy
Number of subjects: 121
Study 9143213 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 121
Study 8504501 — intervention group
Group type: EXPERIMENTAL
Intervention: Autodecremental overdrive pacing
Number of subjects: 24
Study 8504501 — intervention group
Group type: COMPARATOR
Intervention: Low-energy cardioversion
Number of subjects: 24
Study 3593897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g) before ketoprofen (50 mg)
Number of subjects: 6
Study 3593897 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen (50 mg) alone
Number of subjects: 6
Study 3593897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g) before indomethacin (50 mg)
Number of subjects: 6
Study 3593897 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (50 mg) alone
Number of subjects: 6
Study 3593897 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (2 g) before naproxen (500 mg)
Number of subjects: 6
Study 3593897 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (500 mg) alone
Number of subjects: 6
Study 28476259 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg orally for 4 days)
Number of subjects: 100
Study 28476259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27384560 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 0
Study 27384560 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 0
Study 24635755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) 0.5 mg
Number of subjects: 57
Study 24635755 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab (IVR) 0.5 mg + intravitreal triamcinolone acetonide (IVTA) 1 mg
Number of subjects: 57
Study 22086153 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictures method
Number of subjects: 16
Study 22086153 — intervention group
Group type: COMPARATOR
Intervention: Visual analogue scales (VAS)
Number of subjects: 16
Study 20079897 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 as the distension medium
Number of subjects: 264
Study 20079897 — intervention group
Group type: COMPARATOR
Intervention: Normal saline as the distension medium
Number of subjects: 264
Study 18248809 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV screening
Number of subjects: 61149
Study 18248809 — intervention group
Group type: COMPARATOR
Intervention: Cytological screening
Number of subjects: 61149
Study 18248809 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV screening with cytology triage
Number of subjects: 61149
Study 16548351 — intervention group
Group type: EXPERIMENTAL
Intervention: Jieguxujin granule (JGXJG)
Number of subjects: 400
Study 16548351 — intervention group
Group type: COMPARATOR
Intervention: Sanqi tablet (SQT)
Number of subjects: 400
Study 12517464 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant (fluoxetine)
Number of subjects: 450
Study 12517464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 12517464 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment
Number of subjects: 450
Study 10080414 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperkinetic-WMI
Number of subjects: 6232
Study 10080414 — intervention group
Group type: EXPERIMENTAL
Intervention: nonhyperkinetic-WMI
Number of subjects: 6232
Study 10080414 — intervention group
Group type: EXPERIMENTAL
Intervention: hyperkinetic-WMI (as an independent variable)
Number of subjects: 6232
Study 7717553 — intervention group
Group type: EXPERIMENTAL
Intervention: FIO2 = 0.4 (group 1, n = 6)
Number of subjects: 12
Study 7717553 — intervention group
Group type: COMPARATOR
Intervention: FIO2 = 1.0 (group 2, n = 6)
Number of subjects: 12
Study 2127261 — intervention group
Group type: EXPERIMENTAL
Intervention: azidothymidine (AZT)
Number of subjects: 20
Study 2127261 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 7259216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene (DNCB)
Number of subjects: 22
Study 7259216 — intervention group
Group type: COMPARATOR
Intervention: Croton oil
Number of subjects: 22
Study 29659187 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of anastrozole 1.0-mg tablet
Number of subjects: 20
Study 29659187 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of anastrozole (Arimidex 1.0-mg tablet)
Number of subjects: 20
Study 29931719 — intervention group
Group type: COMPARATOR
Intervention: High fat + protein (HFHP) meal
Number of subjects: 15
Study 29931719 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal (carbohydrate-only)
Number of subjects: 15
Study 27411081 — intervention group
Group type: COMPARATOR
Intervention: Back position for catheter insertion
Number of subjects: 88
Study 27411081 — intervention group
Group type: EXPERIMENTAL
Intervention: Right side position for catheter insertion
Number of subjects: 88
Study 25458048 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 0.5 mg/kg
Number of subjects: 50
Study 25458048 — intervention group
Group type: COMPARATOR
Intervention: Morphine 50 μg/kg
Number of subjects: 50
Study 22551976 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA) treatment
Number of subjects: 176
Study 22551976 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 176
Study 20127656 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP) for 24 hours
Number of subjects: 22
Study 20127656 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous blood purification (CBP)
Number of subjects: 22
Study 20127656 — intervention group
Group type: COMPARATOR
Intervention: Patients with MODS (compared to normal controls)
Number of subjects: 22
Study 18242994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegasorb
Number of subjects: 90
Study 18242994 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaderm
Number of subjects: 90
Study 18242994 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 90